Previous 10 | Next 10 |
Summary Investors have punished Integra LifeSciences in FY22, most recently following the recall of its CereLink monitors. The market priced in the downside swiftly and with deep effect, helping shares find a 52-week low. There's now a wide dislocation in measures of corporate...
The U.S. Food and Drug Administration (FDA) on Wednesday classified the recall of several hundred intracranial pressure monitors by Integra LifeSciences ( NASDAQ: IART ) as the most serious type. Integra ( IART ) in June recalled 388 CereLink ICP Monitors in the U.S. d...
Integra LifeSciences Holdings ( NASDAQ: IART ) said the U.S. Food and Drug Administration and other regulatory authorities outside the United States, initiated a voluntary global removal of all CereLink intracranial pressure monitors as customers reported that the monitors...
Integra LifeSciences ( NASDAQ: IART ) said its Founder and Former Chairman and CEO Richard Caruso died during the weekend. Caruso served as chairman from 1992 to 2011, and as CEO from 1992 to 1997. For further details see: Integra LifeSciences founder/fo...
PRINCETON, N.J., Aug. 16, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ:IART), a leading global medical technology company, today announced that Dr. Richard Caruso, founder and former chairman and CEO of Integra LifeSciences passed away over the past weekend...
Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This report optimizes tradi...
Integra LifeSciences Holdings Corporation (IART) Q2 2022 Earnings Conference Call July 27, 2022, 08:30 AM ET Company Participants Chris Ward - Senior Director, Investor Relations Jan De Witte - President & Chief Executive Officer Glenn Coleman - Chief Operati...
The following slide deck was published by Integra LifeSciences Holdings Corporation in conjunction with their 2022 Q2 earnings call. For further details see: Integra LifeSciences Holdings Corporation 2022 Q2 - Results - Earnings Call Presentation
Integra LifeSciences Holdings press release ( NASDAQ: IART ): Q2 GAAP EPS of $0.54 beats by $0.09 . Revenue of $398M (+2.1% Y/Y) beats by $2.62M . Six-month revenues for 2022 were $774 million and increased 3.3% on a reported basis and 5.2% on an organic basis ...
PRINCETON, N.J., July 27, 2022 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corporation (NASDAQ: IART), a leading global medical technology company, today reported financial results for the second quarter ending June 30, 2022. Second Quarter 2022 Highlights Second q...
News, Short Squeeze, Breakout and More Instantly...
Trending Stock
21.25%Change Percent:
Integra LifeSciences Holdings Corporation Company Name:
IART Stock Symbol:
NASDAQ Market:
Integra LifeSciences Holdings Corporation Website:
2024-07-29 18:00:04 ET Ryan Zimmerman from BTIG issued a price target of $22.00 for IART on 2024-07-29 16:12:00. The adjusted price target was set to $22.00. At the time of the announcement, IART was trading at $25.42. The overall price target consensus is at $51.17 with...
2024-07-29 17:15:01 ET BTIG analyst issues SELL recommendation for IART on July 29, 2024 04:12PM ET. IART was trading at $25.42 at issue of the analyst recommendation. The overall analyst consensus : BUY. Current analyst recommendations are : 2 - Buy, 2 - Hold, 1 - Sell ...
2024-07-29 12:23:00 ET Shares of Integra Lifesciences (NASDAQ: IART) were sinking 15.5% as of 11 a.m. ET on Monday. The decline came after the medical technology company announced its second-quarter results before the market opened. Integra reported Q2 revenue of $418.2 million,...